126 related articles for article (PubMed ID: 23594562)
1. HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer.
AbdRaboh NR; Shehata HH; Ahmed MB; Bayoumi FA
Dis Markers; 2013; 34(6):407-17. PubMed ID: 23594562
[TBL] [Abstract][Full Text] [Related]
2. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
Xie D; Shu XO; Deng Z; Wen WQ; Creek KE; Dai Q; Gao YT; Jin F; Zheng W
J Natl Cancer Inst; 2000 Mar; 92(5):412-7. PubMed ID: 10699071
[TBL] [Abstract][Full Text] [Related]
3. P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients.
Kara N; Karakus N; Ulusoy AN; Ozaslan C; Gungor B; Bagci H
DNA Cell Biol; 2010 Jul; 29(7):387-92. PubMed ID: 20380571
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer.
Leite MS; Giacomin LC; Piranda DN; Festa-Vasconcellos JS; Indio-do-Brasil V; Koifman S; de Moura-Neto RS; de Carvalho MA; Vianna-Jorge R
BMC Cancer; 2014 Mar; 14():190. PubMed ID: 24629097
[TBL] [Abstract][Full Text] [Related]
5. HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer.
Ozturk O; Canbay E; Kahraman OT; Fatih Seyhan M; Aydogan F; Celik V; Uras C
Mol Biol Rep; 2013 Feb; 40(2):1813-8. PubMed ID: 23086302
[TBL] [Abstract][Full Text] [Related]
6. The influence of HER2 genotypes as molecular markers on breast cancer outcome.
Mutluhan H; Akbas E; Erdogan NE; Soylemez F; Senli MS; Polat A; Helvaci I; Seyrek E
DNA Cell Biol; 2008 Oct; 27(10):575-9. PubMed ID: 18721072
[TBL] [Abstract][Full Text] [Related]
7. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.
Han X; Diao L; Xu Y; Xue W; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2014 Jun; 25(6):1158-64. PubMed ID: 24608202
[TBL] [Abstract][Full Text] [Related]
8. Association of EGFR and HER2 polymorphisms with risk and clinical features of thyroid cancer.
Rebaï M; Kallel I; Hamza F; Charfeddine S; Kaffel R; Guermazi F; Rebaï A
Genet Test Mol Biomarkers; 2009 Dec; 13(6):779-84. PubMed ID: 19860576
[TBL] [Abstract][Full Text] [Related]
9. Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer.
Muendlein A; Lang AH; Geller-Rhomberg S; Winder T; Gasser K; Drexel H; Decker T; Mueller-Holzner E; Chamson M; Marth C; Hubalek M
J Cancer Res Clin Oncol; 2013 Mar; 139(3):491-8. PubMed ID: 23180020
[TBL] [Abstract][Full Text] [Related]
10. Human epithelial growth factor receptor 2[Ile655Val] polymorphism and risk of breast fibroadenoma.
Zubor P; Kajo K; Stanclova A; Szunyogh N; Galo S; Dussan CA; Minarik G; Visnovsky J; Danko J
Eur J Cancer Prev; 2008 Feb; 17(1):33-8. PubMed ID: 18090908
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia.
Kallel I; Rebai M; Khabir A; Farid NR; Rebaï A
J Biomed Biotechnol; 2009; 2009():753683. PubMed ID: 19636371
[TBL] [Abstract][Full Text] [Related]
12. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.
Akisik E; Dalay N
Exp Mol Pathol; 2004 Jun; 76(3):260-3. PubMed ID: 15126109
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
DeFazio-Eli L; Strommen K; Dao-Pick T; Parry G; Goodman L; Winslow J
Breast Cancer Res; 2011 Apr; 13(2):R44. PubMed ID: 21496232
[TBL] [Abstract][Full Text] [Related]
15. Association between HER2 and IL-6 genes polymorphisms and clinicopathological characteristics of breast cancer: significant role of genetic variability in specific breast cancer subtype.
Bouhniz OE; Zaied S; Naija L; Bettaieb I; Rahal K; Driss M; Kenani A
Clin Exp Med; 2020 Aug; 20(3):427-436. PubMed ID: 32372374
[TBL] [Abstract][Full Text] [Related]
16. Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab.
Singla H; Kaur RP; Shafi G; Vashistha R; Banipal RPS; Kumar V; Munshi A
Mol Biol Rep; 2019 Feb; 46(1):823-831. PubMed ID: 30535550
[TBL] [Abstract][Full Text] [Related]
17. Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.
Flågeng MH; Knappskog S; Haynes BP; Lønning PE; Mellgren G
PLoS One; 2013; 8(8):e74618. PubMed ID: 23991224
[TBL] [Abstract][Full Text] [Related]
18. HER2 polymorphism and breast cancer risk in Portugal.
Pinto D; Vasconcelos A; Costa S; Pereira D; Rodrigues H; Lopes C; Medeiros R
Eur J Cancer Prev; 2004 Jun; 13(3):177-81. PubMed ID: 15167216
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.
Machleidt A; Buchholz S; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
BMC Cancer; 2013 Sep; 13():437. PubMed ID: 24063248
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
Vazquez-Martin A; Colomer R; Brunet J; Lupu R; Menendez JA
Cell Prolif; 2008 Feb; 41(1):59-85. PubMed ID: 18211286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
